Navigation Links
Mylan Reports Second Quarter 2014 Adjusted Diluted EPS of $0.69, In Line With Guidance
Date:8/7/2014

ecessary software. A replay of the webcast will be available at www.mylan.com/investors for a limited time.

Non-GAAP Financial MeasuresThis press release includes the presentation and discussion of certain financial information that differs from what is reported under accounting principles generally accepted in the United States ("GAAP"). These non-GAAP financial measures, including, but not limited to, adjusted diluted EPS, adjusted cash provided by operating activities, adjusted gross profit, adjusted gross margins, adjusted earnings from operations, adjusted interest expense, adjusted net earnings, constant currency total revenue, constant currency third party net sales, adjusted R&D, adjusted SG&A, adjusted tax rate, EBITDA and adjusted EBITDA, are presented in order to supplement investors' and other readers' understanding and assessment of the Company's financial performance. Management uses these measures internally for forecasting, budgeting and measuring its operating performance. In addition, primarily due to acquisitions, Mylan believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with GAAP. In addition, the Company believes that including EBITDA and supplemental adjustments applied in presenting adjusted EBITDA pursuant to our credit agreement is appropriate to provide additional information to investors to demonstrate the Company's ability to comply with financial debt covenants (which are calculated using a measure similar to adjusted EBITDA) and assess the Company's ability to incur additional indebtedness. Set forth below, Mylan has provided reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measure. Investors and other readers are encourag
'/>"/>

SOURCE Mylan Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. Mylan Launches Generic Version of Zyprexa® Tablets
2. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
3. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
4. Mylan Launches Generic Lipitor® in Five European Countries
5. Mylan Launches Generic Version of Plavix® Tablets
6. Mylan Sponsors Drug Store News and Pharmacist Society to Provide a New Business Networking Platform for Pharmacy Schools and Students
7. Mylan Launches Generic Version of Viramune® Tablets
8. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
9. Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovions Brovana® Product
10. Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex®
11. Mylan Launches Generic Version of Lipitor®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Norgine B.V. today ... low volume bowel preparation, NER1006, presented at the 79 ... of Gastroenterology (ACG), Philadelphia, PA , ... weight and co-primary endpoint of cleansing success. The study ... MOVIPREP ® in screening colonoscopy patients. [1] ...
(Date:10/19/2014)... SEATTLE, Wash. , Oct. 20, 2014 ... today that it will report its third quarter 2014 ... close of the U.S. financial markets. Following the announcement, ... conference call to discuss the results and provide a ... PDT). Access to the event can be obtained as ...
(Date:10/18/2014)... , Oct. 18, 2014  In a ... Campaign (HRC), the nation,s largest lesbian, gay, bisexual ... the use of Truvada for Pre-Exposure Prophylaxis (PrEP). ... used to prevent the spread of a disease ... only brand name anti-HIV drug combination currently approved ...
Breaking Medicine Technology:Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 3
... MONTREAL, May 3, 2012 , 2012 First ... of certain dermatology assets , Pro forma organic growth ... and acquisitions, was approximately 11% , 2012 First ... Excluding impact from dermatology divestiture, Cash EPS was $0.99 ...
... SAN DIEGO, May 3, 2012 Optimer Pharmaceuticals, Inc. ... Company will present at the Bank of America Merrill ... AM Pacific Time in Las Vegas, NV. ... webcast of the presentation will be accessible on the ...
Cached Medicine Technology:Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 2Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 3Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 4Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 5Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 6Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 7Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 8Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 9Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 10Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 11Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 12Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 13Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 14Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 15Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results 16
(Date:10/20/2014)... WA (PRWEB) October 20, 2014 My ... workflow management software application. The new module enables ... patients receive full life-cycle quality care. , This application ... others within their practice, attach a to-do item to ... fit, and even set up reoccurring reminders for follow-ups. ...
(Date:10/20/2014)... 20, 2014 Myoderm ... Assistant Director of their CentralSource service. ... the innovative turnkey drug sourcing, distribution, and management ... over 12 years of industry experience, in both ... the peak of their international success to help ...
(Date:10/20/2014)... Fort Collins, CO (PRWEB) October 20, 2014 ... platform, dGH assays are the only imaging assays ... data in a single test.  With these three ... in their ability to detect the widest range ... chromosomal translocations—mutations usually missed by other genomic tools, ...
(Date:10/20/2014)... Ohio (PRWEB) October 20, 2014 Unveiled at ... new Strategic Direction Scorecard conservatively estimates member hospital ROI on ... spent on dues, The Center provides $12.50 in value to ... is (Member Value – Member Dues)/Member Dues. , “This ... at this number and we think the methodology is really ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... his innovative True Form Tummy Tuck® method ... faculty at The University of Texas Medical Branch ... a medical student. Patronella, who is a founding partner ... practices in Texas, The Aesthetic Center for Plastic ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... Lancet Medical Journal reports that vaccination against the sexually transmitted ... girls in Europe//. ,All the girls of the ... of GlaxoSmithKline or with Gardasil of Merck & Co., according ... one in the U.S. in which, a bill passed by ...
... long lasting modifications in the brain metabolism and blood ... and confusion in several cancer survivors. , ... California, Los Angeles, revealed inferior metabolism in the important ... undergone chemotherapy 5-10 years ago.,A spike in blood flow ...
... declared ENBRELR (etanercept) safe to be used to treat psoriasis ... The result of the current studies were presented at the ... is a 'Biologic Medicine which means it is synthesized using ... principles of biotechnology. , , ,This biologic medicine ...
... cancer, such as radiotherapy, surgery and drugs as well ... vary throughout the EU, according to a study published ... 3 October 2006. Access to information is also said ... survey published in Medical OncologyStatus in Europe is a ...
... cause bone loss in older women is likely to ... India//, already caught in a controversy over higher than ... ,American epidemiologists have reported that colas are associated with ... osteoporosis risk for older women. Osteoporosis is a disease ...
... are experiencing unjust dismissal and discrimination at work place ... rights//. ,The Disability Discrimination Act came into ... effective protection at work to people with severe illnesses ... (DRC) has reported that 200 cancer patients had called ...
Cached Medicine News:Health News:Chemotherapy causes mental fog 2Health News:Enbrelr Enters Safer Zone After Recent Research 2Health News:Colas can cause bone loss in old women 2Health News:Injustice to cancer patients at work 2
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: